DLB Dolby Laboratories, Inc. Insider Trading

Todd Pendleton (SVP, CMO) sells 11,876 DLB shares at $54.55; stock -27.7% from 52-week high, 2 of 2 prior DLB sales were 90-day well-timed.

Todd Pendleton sold 11,876 shares for $647,857.18, reducing his holding by -22.3% to 41,480 shares post-transaction. The sale occurred at $54.55, while the stock currently trades at $55.66 and has declined -27.7% from its 52-week high of $77.00. Within his prior trades at Dolby Laboratories specifically, 2 of 2 prior sells (on 2025-02-19 and 2024-02-28) were well-timed at the 90-day mark, with negative subsequent returns of -3.5% and -2.9% respectively. His cross-ticker track record shows a 100.00% 90-day well-timed rate across 3 prior sells with an average 90-day return of -5.6%, suggesting a pattern of selling ahead of stock declines. The current stock weakness (-12.5% over 30 days, -14.9% over 90 days) and position in the broader 52-week drawdown warrant monitoring of whether this sale represents consistent timing discipline or reflects a shift in his asset-allocation strategy.

Dolby Labs CEO Kevin Yeaman sold 33,517 shares in 4 transactions for $2,240,238.36 (blended avg $66.84), reducing holdings 25.4% to 98,377 shares.

Kevin Yeaman, President and CEO of Dolby Laboratories, executed 4 separate sales totaling 33,517 (33.5K shares) for $2,240,238.36 on December 16–17, 2025, at prices ranging from $66.64 to $67.54 with a blended average of $66.84. This sale reduced his holdings from 131,894 to 98,377 shares, a net reduction of 25.4% of pre-transaction holdings. The timing is noteworthy: his prior sells at DLB have not demonstrated a pattern of well-timed exits (0 of 0 prior measurable sells at the 90-day mark were well-timed), and his broader cross-ticker track record shows a 64.29% well-timed rate on 19 prior sells with average 90-day returns of -3.0%. The current stock price of $67.14 sits 23.1% below the 52-week high of $87.32, suggesting the sales occurred during a period of weakness, though the stock is up 4.0% over the prior 30 days.

Dolby CEO Yeaman sells 34,367 shares for $2,305,492.57 via pre-arranged 10b5-1 plan

Kevin Yeaman, President and CEO of Dolby Laboratories, conducted 2 separate sales totaling 34,367 shares for $2,305,492.57 on 2025-12-09 at a blended average price of $67.08. This sale reduced his holdings from 132,744 shares to 98,377 shares, a decrease of 25.9% of his pre-transaction position. The transaction was executed under a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. As a scheduled sale under a 10b5-1 plan, this transaction reflects contractual obligations established in advance and does not indicate a timing-based market judgment by the CEO.

CEO Kevin J Yeaman sold 36,699 DLB shares at $66.91 (Nov 2025) under 10b5-1 plan; post-sale stake 98,377 shares

CEO Kevin J Yeaman executed a sale of 36,699 shares for $2,455,405.31 as part of a pre-arranged 10b5-1 trading plan adopted on 2025-02-28, reducing his holdings from 135,076 shares to 98,377 shares (-27.2%). Because this transaction was scheduled under a formalized trading plan rather than discretionary, it does not reflect timing-based judgment or current views on valuation. The sale represents a material reduction in his direct ownership stake, though he retains substantial equity exposure at 98,377 shares post-transaction. The automated nature of the execution removes it from the category of opportunistic insider trading signals.

DLB CEO Kevin J Yeaman sold 25,000 shares for $1,721,841.90 via 10b5-1 plan on 2025-10-14

Kevin J Yeaman, President and CEO of Dolby Laboratories, executed two separate sales totaling 25,000 shares (11,214 shares at $68.51 on 2025-10-14 and 13,786 shares at $69.17 on 2025-10-14) for $1,721,841.90 combined, reducing his holdings from 139,725 shares to 114,725 shares. This transaction is part of a pre-arranged 10b5-1 trading plan, meaning it was scheduled in advance and not a discretionary trade decision. The sale represents a -17.9% reduction in his pre-transaction holdings. As a scheduled transaction executed under a Rule 10b5-1 trading plan, this sale carries reduced signaling value regarding insider conviction or market timing views.

DLB CEO YEAMAN KEVIN J sold 25,000 shares at $71.66 on 2025-09-16; stock down 2.3% over 30 days post-sale

Kevin J Yeaman, President and CEO of Dolby Laboratories, executed an open-market sale of 25,000 shares on 2025-09-16 at $71.66, reducing his holdings from 139.7K to 114.7K shares (-17.9% of pre-transaction position) for total proceeds of $1.8M. The stock has since declined 2.3% over 30 days—consistent with his prior sells at DLB where 4 of 5 recent transactions preceded negative 30-day returns (ranging from -0.3% to -3.7%), though longer-term outcomes at this ticker remain unmeasurable. His broader cross-ticker track record shows 19 prior sells with a 42.86% well-timed rate and neutral 90-day average returns (-0.5%), indicating no systematic pattern of prescient exit timing. The company's fundamentals show modest headwinds: annual revenue declined 2.0% year-over-year to $315.5M, net income stands at $46.1M, and the stock trades at a 26.31 P/E, -17.4% below its 52-week high of $87.32. This sale is routine for a CEO managing a large concentrated position within a mature, stable business.

CEO Kevin Yeaman sold 25,000 DLB shares at $72.31; holds 114.7K shares post-sale. Stock -16.9% from 52-week high.

Kevin Yeaman, President and CEO of Dolby Laboratories, sold 25,000 shares on 2025-08-12 at $72.31, reducing his holdings by 17.9% to 114,725 shares. The stock is currently trading at $72.53, down 16.9% from its 52-week high of $87.32 and down 6.5% over the prior 90 days. Across his cross-ticker track record, Yeaman's 19 prior sells posted an average 90-day return of +0.7% with a 30.77% well-timed rate; however, his same-ticker history at DLB shows 5 prior sales with mixed short-term outcomes (ranging from -3.7% to +3.1% at 30 days), and no measurable 90-day results yet on which to evaluate patterns. At present, Yeaman retains a substantial position of 114.7K shares, consistent with continued stake ownership despite the sale.

DLB CEO Kevin Yeaman sold 42,366 shares for $3,170,114.80 via 10b5-1 plan

Kevin Yeaman, President and CEO of Dolby Laboratories, executed 3 separate sales totaling 42,366 shares for $3,170,114.80 on July 15-16, 2025, at a blended average price of $74.83. This transaction reduced his holdings from 157,091 shares to 114,725 shares, a decline of 27.0% from pre-transaction levels. The sales were executed under a pre-arranged 10b5-1 trading plan, meaning this was a scheduled transaction rather than a discretionary trade, and therefore carries no inference about near-term company prospects or market timing judgment.

CEO Kevin Yeaman sold 25,000 DLB shares at $74.02; post-sale holding 114,725 shares (-17.9%)

Kevin Yeaman, Dolby's President and CEO, sold 25,000 shares for $1,850,530.00, reducing his holdings by 17.9% to 114,725 shares. His cross-ticker track record shows 19 prior sells with a 41.18% well-timed rate (sales occurring before subsequent declines), though at Dolby specifically, 0 of 3 prior measurable sells were well-timed—each was followed by positive 90-day returns ranging from +0.5% to +1.5%. The current share price of $74.82 is 14.3% below the 52-week high, and the stock has declined 6.4% over 90 days. Dolby's fundamentals show trailing quarterly revenue of $369.6M with net income of $91.8M, but annual revenue contracted 2.0% year-over-year, creating context for a material reduction in CEO equity holdings.

CEO Kevin Yeaman sells 33,683 shares for $2,567,481.42; holdings drop 22.7% to 114,725 shares.

Kevin Yeaman, President and CEO of Dolby Laboratories, executed 2 separate sales totaling 33,683 shares for $2,567,481.42 at a blended average price of $76.22. This represents a substantial reduction in his stake, with post-transaction holdings falling 22.7% from 148,408 to 114,725 shares. The timing is notable: the stock trades at $75.23 currently, near the lower end of its 52-week range and down 13.8% from its high, yet in his prior 5 same-ticker sales at DLB, the insider was never well-timed on a 90-day horizon (0 of 5 had negative post-sale returns). His cross-ticker sell track record shows a 42.11% well-timed rate with an average 90-day return of -0.3%, suggesting neither a strong directional pattern nor conviction about downside risk at this moment. The company's fundamentals remain solid (Q-latest revenue $369,561,000.00, net income $91,793,000.00, P/E 27.46), though annual revenue growth is negative at -2.0%. This sale reflects a material reduction in insider ownership but does not clearly signal forward-looking concern given the mixed prior execution timing and stable operational metrics.